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ABSTRACT
Objectives: The main aim of the study was to evaluate the impact of levels of serum soluble receptor-binding cancer an-
tigen expressed on SiSo cells (sRCAS1) on the overall survival (OS) rates in patients with endometrial cancer. Furthermore, 
we analyzed sRCAS1 levels according to the clinicopathological characteristics of the disease. 
Material and methods: The study group comprised 43 patients who were being treated for endometrial cancer. We 
included 10 low-risk, 20 intermediate-risk and 13 high-risk endometrial cancers using the criteria of the European Society 
for Medical Oncology (ESMO), the European Society for Radiotherapy & Oncology (ESTRO) and the European Society of 
Gynaecological Oncology (ESGO). Serum sRCAS1 levels were obtained before and after surgery. Serum sRCAS1 levels were 
assessed using the ELISA method. 
Results: In our univariate analysis, both the pre- and post-surgery high sRCAS1 groups of patients with endometrial cancer 
indicated a shortened OS. However, in our multivariate analysis, when patients’ age and disease-related risk was taken into 
consideration, only the post-surgery sRCAS1 levels remained as independent prognostic factors of a poor OS. Pre-treatment 
serum sRCAS1 levels were statistically significantly higher than post-surgery sRCAS1 levels; however, the difference between 
pre- and post-surgery sRCAS1 levels did not influence the patients’ OS rate. Pre- and post-surgery sRCAS1 levels did not 
differ according to tumor grade, stage of the disease or the disease-related risk group. 
Conclusions: High post-surgery serum sRCAS1 levels seem to be an independent indicator of shortened overall survival 
in patients with endometrial cancer.
Key words: sRCAS1; RCAS1; receptor-binding cancer antigen expressed on SiSo cells; endometrial cancer; cancer im-
munology
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INTRODUCTION
Endometrial cancer is the most common gynecologic 
cancer and it is the fifth most common cancer in women. 
Due to the early manifestation of symptoms endometrial 
cancer possess favorable prognosis, and it is the fourteen 
cancer in terms of women’s mortality [1, 2]. However, even in 
the cases of localized endometrial cancers (FIGO IA and IB), 
the 5-year survival rate is 88% for the former (IA) and 75% 
for the latter (IB) [3]. That means that a significant proportion 
of the risk factors of patients with early stage endometrial 
cancer have been underestimated. Endometrial cancer is 
predominantly diagnosed in elderly patients, who are more 
prone to the adverse outcomes of adjuvant therapy. Thus, 
adjusted risk stratification may mean that unnecessary adju-
vant therapy is abandoned. On the other hand, the incidence 
of endometrial cancer is increasing and it is now increasingly 
being diagnosed in premenopausal women, and even in 
women younger than 40 years of age (5%) [1]. This group 
of premenopausal patients is at increased risk of long-term 
adverse outcomes of radiotherapy. Furthermore, due to 
the present trend in delayed childbearing, fertility-sparing 
has become an important consideration in the treatment 
135
Sebastian Szubert et al., sRCAS1 serum levels in endometrial cancer
www. journals.viamedica.pl/ginekologia_polska
of patients with endometrial cancer [4]. Adjuvant therapy 
in cases of endometrial cancer is still being debated [5]. Es-
pecially the exact role of adjuvant chemotherapy in higher 
risk patients is still not fully elucidated [6]. Thus, evaluation 
of all prognostic factors is required before any final decision 
about adjuvant management can be made [6]. 
Currently, the prognosis for endometrial cancer is pre-
dominantly based on the FIGO stage of the disease, the 
histopathological type of the tumor, histopathological grade 
and the lymphovascular space invasion (LVSI) status. Based 
on these aforementioned factors, the European Society for 
Medical Oncology (ESMO), the European Society for Radio-
therapy & Oncology (ESTRO) and the European Society of 
Gynaecological Oncology (ESGO) proposed new categories 
of risk groups to guide adjuvant therapy in patients with 
endometrial cancer [6]. However, risk stratification may also 
be evaluated using biological markers of cancerogenesis. For 
instance, a pooled analysis of PORTEC trial results indicated 
high L1 cell adhesion molecule (L1CAM) expression as an in-
dependent predictor for poor overall survival [7]. 
Receptor-binding cancer antigen expressed on SiSo cells 
(RCAS1) was discovered in 1996 by Sonoda et al. [8] as a mem-
brane protein present on cervical cancer cells. RCAS1 expression 
was found on a variety of cells, including T, B, and NK cells, and 
on macrophages, fibroblasts, and human neoplastic cells [9]. 
RCAS1 acts through the putative receptor, and its main func-
tion is related to the induction of selective immunosuppres-
sion. In the study by Nakashima et al. [10–12], authors showed 
that RCAS1 induces the arrest of cell growth and apoptosis in 
T, B and NK cells. Furthermore, immunohistochemical stud-
ies have shown an association between RCAS1 expression 
and the number of apoptotic lymphocytes and a negative 
correlation between RCAS1 expression and the quantity of 
tumor-infiltrating lymphocytes [13–15]. Despite the immu-
nosuppressive activity of RCAS1, the protein can also contrib-
ute to tumor stroma remodelling creating a tumor-friendly 
microenvironment [16–18]. Specifically, RCAS1 interacts with 
noncancerous stromal cells (tumor associated macrophages, 
and cancer associated fibroblasts) to stimulate angiogenesis 
through VEGF, and its expression correlates with extracellular 
matrix proteases expression [16, 19–21].
RCAS1 can be secreted in the soluble form (sRCAS1) in 
the process of ectodomain shedding to the tumor microen-
vironment, and then to the blood system. Sonoda et al. [22], 
have shown that sRCAS1 also possesses an immunosuppres-
sive capability, as it induces apoptosis of immune cells. Ad-
ditionally, in their study of patients with cervical and endo-
metrial cancer, Sonoda et al., showed there was a negative 
correlation between sRCAS1 and the number of peripheral 
blood lymphocytes [23].
Numerous studies have shown that tumor RCAS1 expres-
sion is an indicator of poor prognoses in patients with cancer 
[16, 24–29]. However, there is sparse data on serum sRCAS1 lev-
els as a prognostic factor in human malignancies, and most of 
the data that does exist relates to the evaluation of short term 
outcomes [23]. From a clinical point of view, the most informa-
tive prognostic factors are those that influence patients’ overall 
survival (OS) [28, 30]. To the best of our knowledge, there is no 
study evaluating the influence of serum sRCAS1 levels on the 
OS rates of patients with endometrial cancer. 
Objectives
The main aim of our study was to evaluate the impact of 
pre- and post-surgery sRCAS1 levels on the overall survival 
rates in patients with endometrial cancer. Furthermore, we 
looked for correlations between sRCAS1 levels and clinico-
pathological features of the disease. 
MATERIAL AND METHODS
Human subject
The study included 43 patients diagnosed with and 
treated for endometrial cancer. The median patient age was 
65 and ranged from 43 to 84. The patients underwent treat-
ment either in the Gynecology and Oncology Department 
of the Lukaszczyk Oncological Centerin Bydgoszcz or in the 
Gynecologic Oncology Department of the M. Sklodows-
ka-Curie Memorial Institute in Krakow between 2007 and 
2010. The patients were recruited consecutively from pa-
tients with newly diagnosed endometrial cancer admitted 
to our Departments for surgical treatment. Patients with sig-
nificant co-morbidities, including, autoimmune connective 
tissue diseases or patients during immunosuppression, were 
excluded from the study. The study group included 37 pa-
tients with endometrioid adenocarcinomas, 2 with serous 
adenocarcinomas, one with adenosquamous carcinoma, 
one with clear-cell adenocarcinoma, one with carcinosar-
coma and one with an undifferentiated carcinoma. The FIGO 
stages of the cancer patients were as follows: 1A — 11 pa-
tients; 1B — 22 patients; II — 2 patients; IIIA — 4 patients; 
IIIB —2 patients; and IIIC — 2 patients. Twenty-two tumors 
had G1 cancer, while 16 and 5 tumors were graded as G2 and 
G3 respectively. Using the combined consensual criteria of 
the European Society for Medical Oncology (ESMO), the 
European Society for Radiotherapy & Oncology (ESTRO) 
and European Society of Gynaecological Oncology (ESGO), 
the patients with endometrial cancers were divided into 
groups relating to the risk level of the disease. The study 
included 10 low-risk endometrial cancers (endometrioid 
type, grade 1–2, FIGO IA, LVSI negative), 20 intermediate-risk 
endometrial cancers (endometrioid type, grade 1–2, FIGO IB, 
LVSI negative), and 13 high-risk endometrial cancers (FIGO 
stage II or above, or non-endometrioid types). There were no 
“high-intermediate”, “advanced” or “metastatic” risk groups 
among the endometrial cancers. For the survival analyses, 
136
Ginekologia Polska 2019, vol. 90, no. 3
www. journals.viamedica.pl/ginekologia_polska
both low- and intermediate-risk cancers were included in 
a single subgroup.
We analyzed sRCAS1 levels in serum blood samples ob-
tained both before and after surgery. Patients were treated 
with total abdominal hysterectomy with bilateral adnexec-
tomy, and pelvic with/without paraaortic lymphadenecto-
my. Omentectomy was performed when serous endometrial 
adenocarcinoma was diagnosed. The low- and intermedi-
ate-risk group patients were either carefully followed-up 
postoperatively or they received brachytherapy. High-risk 
patients received chemoradiation.  
Blood samples from patients treated surgically were 
collected directly prior to surgery and on the fourth day 
following hysterectomy. Blood samples were collected in 
a serum collection tube. A clot was permitted to form at 
room temperature for 30–60 minutes. The tube was placed 
on ice for 30 minutes to allow the clot to contract. The serum 
samples were then centrifuged at 3000x for 10 minutes at 
room temperature. Next, 1.0–2.0 mL samples were collected 
from the supernatants and stored at -80°C.
Each of the patients gave their written informed consent. 
Prior to the study, we obtained approval from the Jagiel-
lonian University Ethical Committee (KBET/135/B/2007). 
Information on any patients who died was retrieved from 
the database of the Cuiavia-Pomerania and Lesser Poland 
National Health System of Poland. We analyzed patients’ over-
all survival (OS) rates with respect to pre- and post-interven-
tional sRCAS1 levels as well as with respect to the differences 
between pre- and post-surgery levels. The median follow-up 
period for patients was 1593 days (range 138–2468). 
sRCAS1 levels assessment
The analysis of sRCAS1 concentrations in the serum sam-
ples was performed in the Department of Analytical Biochem-
istry, Faculty of Biochemistry, Biophysics, and Biotechnology, 
Jagiellonian University. We used a commercially avalible ELISA 
kit for sRCAS1 detection (Medical & Biological Laboratories Co. 
Ltd, Nagoya, Japan). Briefly, the diluted serum samples were 
pre-treated with neuraminidase and incubated in the wells 
of the plates coated with anti-human RCAS1 monoclonal an-
tibodies. After washing, the wells were incubated with biotin 
conjugated anti-RCAS1 antibodies, and this procedure was 
followed by a second washing and incubation of the wells with 
a streptavidin-peroxidase conjugate. Following a third wash-
ing, color reaction was developed using the tetramethylbenzi-
dine/hydrogen peroxide substrate. The reaction was stopped 
by acidification of the contents of the wells, and the plates 
were then read at 450 nm on a microplate reader. The plates 
were individually calibrated by a quantitative sRCAS1 refer-
ence standard provided by the manufacturer of the set and 
expressed in arbitrary units (U/mL). The correlation coefficient 
of the dose-response curves we obtained was above 0.99. 
Statistical analysis
The distribution of variables in the study groups was 
verified using the Shapiro-Wilk test. Parametric or non-par-
ametric tests were used for evaluation according to data 
distribution. The difference between pre- and post-surgery 
sRCAS1 levels was investigated using Wilcoxon matched-pairs 
test. The differences between sRCAS1 levels according to 
tumor grade were investigated with the use of Kruskal-Wallis 
test, both in pre- and post-intervention group. The differences 
in sRCAS1 levels between low/intermediate and high-risk 
patients, and between FIGO I and FIGO II/III stage disease 
were evaluated using Mann-Whitney test, both in pre-and 
post-intervention group. The correlation between patient age 
and sRCAS1 levels was evaluated using Spearman Rank cor-
relation. Survival analysis was conducted using Kaplan-Meier 
survival curves. The cut-offs between “high” and “low” pre- and 
post-surgery sRCAS1 levels were determined following OS 
analyses; namely that we have analyzed different cut-offs, and 
the level with the lowest P-value was chosen. Multivariate sur-
vival analysis was conducted using Cox proportional-hazards 
regression with the stepwise entering method. 
RESULTS
Survival analysis
Patients’ pre-treatment sRCAS1 levels below 10 U/mL 
(36 women) were associated with statistically significant 
longer overall survival when compared with patients with 
pre-treatment sRCAS1 levels above 10 U/mL (7 women). Simi-
larly, postoperative sRCAS1 levels below 8 U/mL (33 women) 
indicated longer OS when compared with patients with sR-
CAS1 levels above 8 U/mL (10 women). The variation of sR-
CAS1 levels after treatment was not associated with patients’ 
survival. Serum sRCAS1 levels were found to be decreased 
more than 10% in 20 women, while 23 patients had either sta-
ble or increased sRCAS1 levels after treatment (this subgroup 
included patients either with a decrease of less than 10% or 
a stable level, or an increased sRCAS1 level). Patients with 
sRCAS1 levels decreasing more than 10% had median survival 
not significantly different from that of the rest of the group.
We have found the patient survival to be related with 
patients’ age. Patients older than 65 (23 women) had sig-
nificantly shortened survival when compared with patients 
younger than 65 (20 women).
Patients with high-risk endometrial cancers (13 patients) 
had significantly shortened survival when compared with the 
patients with low- and intermediate-risk endometrial cancers 
(30 patients). In the multivariate survival analysis, only postop-
erative sRCAS1 levels (P = 0.03), patients’ ages (P = 0.02), and the 
risks group according to ESMO-ESGO-ESTRO criteria (P = 0.02) 
were independent predictors of patients’ overall survival rates. 
Survival curves are presented in Figure 1. The results of 
our analysis are summarized in Table 1.
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sRCAS1 levels and clinicopathological features 
of the disease 
Pre-treatment serum sRCAS1 levels were statistically 
significantly higher than postoperative sRCAS1 levels 
(7.35 U/mL, range 3.40–66.16 compared with 6.85 U/mL, 
range 3.76–31.78, respectively; P = 0.0001). 
We did not observe differences in pre- and post-surgery 
sRCAS1 levels regarding the grade of the tumor. Similarly, 
pre- and post-surgery sRCAS1 levels were not related either 
with FIGO stage of the disease or with the risk group. The 
results of the sRCAS1 assessment regarding the clinico-
pathological features of the disease we analyzed are sum-
marized in Table 2.
The low-intermediate and high-risk groups of 
patients were not different in terms of patient age 
(60.4 ± SD 9.26 compared with 60.52 ± SD 10.34, respec-
tively; P = 0.37).
Pre-treatment sRCAS1 levels were positively correlated 
with patients’ age (R Spearman = 0.37, P = 0.01). Similarly, 
postoperative sRCAS1 levels were positively correlated with 
patients’ ages (R Spearman = 0.36, P = 0.02). 
DISCUSSION
In the present study, our univariate survival analysis has 
shown that high sRCAS1 levels in both pre- and postopera-
tive patients were predictive factors of shortened survival 
rates for endometrial cancer patients. However, when other 
prognostic factors, like disease specific risk and patients’ 
ages were taken into consideration, only high postopera-
tive sRCAS1 levels was associated with patients’ overall 
Figure 1. Analysis of patients’ survival. A) Pre-treatment sRCAS1 levels. Group 1) below 10 U/mL (median survival: 3853 days, range 55–4117); 
Group 2) above 10 U/mL (1496 days, range 279–3967, P = 0.035). B) Postoperative sRCAS1 levels. Group 1) below 8 U/mL (median survival: 3855 
days, range 336–4117); Group 2) above 8 U/mL (2116, range 55–3967; P = 0.043). C) Variation of sRCAS1 levels after treatment — the difference 
between postoperative and pre-surgery levels. Group 1) sRCAS1 levels decrease above 10% (median survival: 3889 days range 279–4104); Group 
2) decrease below 10% and stable or increased sRCAS1 levels(3826 days, range 55–4117; P = 0.80). D) Survival according to patient age. Group 1) 
patients younger than 65 (median survival 3917 days, range 55–4117); Group 2) patients older than 65 (2854 days, range 138–4111, P = 0.01).  
E) Survival according to disease specific risk. Group 1) low- and intermediate-risk endometrial cancers (median survival: 3904 days, range 336–
4084); Group 2) high-risk endometrial cancers (2975 days, range 55–4117; P = 0.04).
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survival rates. Our results may indicate, that the intensity 
of the selective suppression of the host’s immune system 
and the tumor stroma modulation related to RCAS1 func-
tion are reflected in the patients’ prognoses. In an earlier 
research study, Sonoda et al. [31], showed that high tumor 
RCAS1 expression was associated with shortened OS. In that 
study, patients’ survival was progressively correlated with 
the degree of RCAS1 expression. Similarly, RCAS1 expres-
sion was an independent prognostic factor in multivariate 
analysis [31]. From a clinical point of view, analysis of serum 
markers is more feasible and less subjective when compared 
with immunohistochemical tumor analysis. Additionally, 
serum sRCAS1 levels are also available for patients who are 
not operated upon. Thus, for practical purposes, serum sR-
CAS1 levels seem to be more a useful prognostic factor when 
compared with evaluations of tumor RCAS1 expression. 
RCAS1 expression has been shown to progress from 
the normal endometrium, through premalignant lesions, to 
invasive carcinomas [32, 33]. Sonoda et al. [31], showed there 
is an association between RCAS1 expression in endometrial 
cancer and the clinical stage of the disease. Similarly, Zhou 
et al. [33], observed higher RCAS1 expression in endometrial 
cancer characterized by deep myometrial and vascular inva-
sion. In an earlier study by Sonoda et al. [32], the authors 
reported that there was higher RCAS1 expression in grade 3 
Table 1. Survival analysis according to pre- and post-surgery serum sRCAS1 levels
Univariate Survival Analysis
Groups Survival P-Value
Pre-treatment sRCAS1 levels
below 10 U/mL (36 patients) 3853 days, range 55 –4117
P = 0.035
above 10 U/mL (7 patients) 1496 days, range 279–3967
Postoperative sRCAS1
below 8 U/mL (33 patients) 3855 days, range 336–4117
P = 0.043
above 8 U/mL (10 patients) 2116, range 55–3967
Variation insRCAS1 levels 
after treatment
decrease above 10% (20 patients) 3889 days, range 279–4104
P = 0.80decrease below 10% and stable or increased 
sRCAS1 levels
(23 patients)
3826 days, range 55–4117
Patients’ age
older than 65 (23 patients) 2854 days, range 138–4111
P = 0.01
younger than 65 (20 patients) 3917, range 55–4117
Risk group
Low- and intermediate-risk (30 patients) 3904 days, range 336–4084
P = 0.04
High-risk (13 patients) 2975 days, range 55–4117
Multivariate Survival Analysis
P-value 95% CI P-Value
Patients’ age P = 0.02 1.34–17.83
P = 0.0025
Risk group P = 0.02 1.16-10.14
Pre-treatment sRCAS1 levels Not included
Postoperative sRCAS1 P = 0.03 1.12–10.77
Risk associated with the disease was stratified according to ESMO-ESGO-ESTRO criteria. We have used Cox proportional-hazards regression multivariate survival with 
the stepwise entering method. Pre-treatment sRCAS1 levels were not included in the calculation due to the nonsignificant impact on patients’ survival rates in the 
multivariate analysis. 
Table 2. Pre- and postoperative sRCAS1 levels according to the 
tumor grade, FIGO stage of the disease and the risk group related 
to endometrial cancer
Pre-treatments sRCAS1 levels
Median U/mL (range) P-Value
G1 7.35 (4.16–10.75)
P = 0.23G2 6.52 (3.40–66.16)
G3 7.82 (6.56–31.23)
FIGO I 6.94 (3.40–42.25)
P = 0.17
FIGO II - III 7.75 (3.91–66.16)
Low- and 
intermediate-risk 6.96 (3.4-42.25) P = 0.78
High-risk 7.69 (4.16–42.25)
Postoperative sRCAS1 levels
Median U/mL (range) P-value
G1 6.73 (3.76–17.15)
P = 0.73G2 6.51 (3.76–31.78)
G3 6.13 (5.80–23.08)
FIGO I 6.69 (3.74–23.08)
P = 0.37
FIGO II - III 6.76 (5.54–31.78)
Low- and 
intermediate-risk 6.56 (3.76–17.15) P = 0.23
High-risk 6.75 (5.54–31.78)
Risks groups associated with the disease were stratified according to ESMO-
ESGO-ESTRO criteria
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endometrial cancers when compared with grade 1 and 
2 tumors. However, it seems that there is lack of association 
between serum sRCAS1 levels and the clinicopathological 
characteristics of endometrial cancer. Sonoda et al. [23], have 
evaluated serum sRCAS1 levels in fifty patients with endo-
metrial cancer. These authors showed that there were higher 
pretreatment sRCAS1 levels in the patients with endometrial 
cancer compared with those of the healthy controls. How-
ever, serum sRCAS1 concentrations were not correlated 
with clinical stage, histologic type, grade, or lymph node 
metastasis [23]. This finding concurs with our observa-
tions. Namely, we did not observed differences between 
pre- and postoperative sRCAS1 levels according to tumor 
grade or the FIGO stage of the disease. Furthermore, in our 
study, we have found no association between sRCAS1 levels 
and the risk groups according to ESMO-ESGO-ESTRO crite-
ria. This observation is very important, because it suggest 
that serum sRCAS1 levels may serve as a prognostic factor 
independent from clinical features of the disease. However, 
the results of our study should be interpreted with caution 
because of the small number of cases. 
Sonoda et al. [23], showed there are decreased levels 
of sRCAS1 after successful treatment.We also observed de-
creased levels of sRCAS1 following hysterectomy. However, 
we did not observe any relationship between the degree of 
sRCAS1 level changes and the patients’ prognoses. There-
fore, we conclude that while sRCAS1 levels decrease after 
treatment for endometrial cancer, patients’ prognoses are 
more related to the absolute levels of sRCAS1. 
We observed a strong correlation between both pre- 
and postoperative sRCAS1 and patient age. In the study by 
Sonoda et al. [23], serum sRCAS1 levels were not associated 
with patient age. The possible explanation of this discrep-
ancy is that Sonoda et al. studied a single group combining 
endometrial and cervical cancer patients, although these 
two cancers occur in different age groups. However, another 
study by Sonoda et al. [31], reported a strong and positive 
correlation between tumor RCAS1 immunoreactivity and 
patient age. Patients’ age is in general regarded as a nega-
tive prognostic factor in endometrial cancer [34, 35]. Our 
results confirm this observation, because advanced age was 
associated with shortened survival. Although in our study 
sRCAS1 levels were correlated with patient age, in our mul-
tivariate analyses, both patient age and sRCAS1 levels were 
shown to be independent prognostic factors of patient OS. 
In conclusion, we have found that elevated serum sR-
CAS1 were shown to be associated with shortened overall 
survival in patients with endometrial cancer. However, more 
prospective studies are needed to confirm or reject the 
hypothesis that the serum sRCAS1 levels could be used to 
predict the OS in women treated for endometrial cancer.
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